Shopping Cart
- Remove All
- Your shopping cart is currently empty
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM and is applicable in pulmonary arterial hypertension research. It demonstrates high selectivity for its target compared to PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11, and it possesses oral bioavailability.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM and is applicable in pulmonary arterial hypertension research. It demonstrates high selectivity for its target compared to PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11, and it possesses oral bioavailability. |
Targets&IC50 | PDE11A:>100000 nM |
In vitro | PDE5-IN-13's C3 cyanide group forms hydrogen bonds with D76 and H613 through a water molecule, thereby stabilizing the binding conformation of PDE5-IN-13 [1]. |
In vivo | PDE5-IN-13 (1500 mg/kg, p.o.) shows no acute toxicity in mice [1]. In a rat model of Monocrotalin-induced pulmonary arterial hypertension, PDE5-IN-13 (5.0 mg/kg, p.o., daily for 21 days) is significantly more effective than Sildenafil citrate (10.0 mg/kg) at increasing mPAP (mean pulmonary artery pressure) and reducing RVHI (right ventricular hypertrophy index). |
Molecular Weight | 486.564 |
Formula | C31H26N4O2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.